Cargando…
A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them
Autor principal: | Yoshida, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japan Atherosclerosis Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392476/ https://www.ncbi.nlm.nih.gov/pubmed/28239069 http://dx.doi.org/10.5551/jat.ED069 |
Ejemplares similares
-
Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2017) -
Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
por: Stefanutti, Claudia
Publicado: (2020) -
Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2023) -
Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Kameyama, Noriko, et al.
Publicado: (2019) -
Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting
por: Mahzari, Moeber, et al.
Publicado: (2021)